X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-08-28 | XENE | Xenon Pharmaceuticals Inc. | Kenney Christopher John | Chief Medical Officer | S - Sale | $60.25 | -7,068 | 2 | -100% | -$425,829 | ||||||
| DM | 2026-08-27 | ODD | Oddity Tech Ltd | Drucker Mann Lindsay | Global CFO | S - Sale+OE | $14.85 | -39,360 | 116,135 | -25% | -$584,451 | |||||
2026-08-31 | FENC | Fennec Pharmaceuticals Inc. | Sayad Pierre Sargis | Chief Medical Officer | S - Sale | $12.18 | -12,000 | 9,519 | -56% | -$146,160 | ||||||
| D | 2026-08-27 | ARTV | Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Chief Medical Officer | S - Sale+OE | $12.01 | -8,222 | 142,047 | -5% | -$98,736 | |||||
| D | 2026-08-28 | CBT | Cabot Corp | Keohane Sean D | Pres, CEO | S - Sale+OE | $85.00 | -134,895 | 418,398 | -24% | -$11,466,075 | |||||
| D | 2026-08-27 | JAZZ | Jazz Pharmaceuticals Plc | Iannone Robert | EVP, Global Head of R, D, CMO | S - Sale+OE | $249.70 | -76,921 | 65,686 | -54% | -$19,207,098 | |||||
| D | 2026-08-28 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $27.58 | -7,500 | 26,250 | -22% | -$206,824 | |||||
| M | 2026-08-27 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.P. | 10% | S - Sale | $7.08 | -86,914 | 4,231,434 | -2% | -$615,777 | |||||
| M | 2026-08-27 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $7.08 | -86,914 | 4,231,434 | -2% | -$615,777 | |||||
| M | 2026-08-28 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $69.19 | +40,330 | 540,217 | +8% | +$2,790,326 | |||||
2026-08-27 | CAMP | Camp4 Therapeutics Corp | Schwab Andrew J. | Dir | S - Sale | $4.04 | -400,000 | 5,277,216 | -7% | -$1,616,000 | ||||||
| D | 2026-08-27 | COGT | Cogent Biosciences, Inc. | Morris Arlene | Dir | S - Sale+OE | $37.12 | -45,510 | 0 | -100% | -$1,689,493 | |||||
| D | 2026-08-31 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $70.24 | -10,000 | 58,555 | -15% | -$702,400 | |||||
| D | 2026-08-31 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $70.24 | -7,500 | 381,986 | -2% | -$526,800 | |||||
| D | 2026-08-28 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $517.51 | -9,500 | 668,728 | -1% | -$4,916,363 | |||||
2026-08-27 | VRXA | Veraxa Biotech AG - Post De-Spac | Baumann Oliver Rolf | Dir | P - Purchase | $1.50 | +50,000 | 5,773,618 | +1% | +$75,000 | ||||||
2026-08-27 | VRXA | Veraxa Biotech AG - Post De-Spac | Antz Christoph Rudiger | CEO | P - Purchase | $1.53 | +5,000 | 5,000 | New | +$7,650 | ||||||
| D | 2026-08-28 | EL | Estee Lauder Companies Inc | La Lande Rashida | EVP, GC | S - Sale+OE | $103.32 | -7,766 | 0 | -100% | -$802,383 | |||||
| AD | 2026-08-28 | ETON | Eton Pharmaceuticals, Inc. | Maier Paul V | Dir | S - Sale+OE | $59.07 | -50,000 | 72,245 | -41% | -$2,953,572 | |||||
2026-08-31 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +3,500 | 9,384,256 | 0% | +$172 | ||||||
2026-08-27 | TNXP | Tonix Pharmaceuticals Holding Corp. | Lederman Seth | CEO | P - Purchase | $13.79 | +2,000 | 31,007 | +7% | +$27,580 | ||||||
2026-08-26 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | S - Sale | $1.56 | -2,000 | 127,777 | -2% | -$3,116 | ||||||
| A | 2026-04-14 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | P - Purchase | $1.01 | +110,388 | 129,777 | +569% | +$110,965 | |||||
| A | 2026-04-14 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | P - Purchase | $1.01 | +110,388 | 129,777 | +569% | +$110,965 | |||||
2026-08-28 | BIVI | Biovie Inc. | Palumbo Joseph M | Chief Medical Officer | P - Purchase | $2.16 | +4,843 | 6,036 | +406% | +$10,461 | ||||||
2026-08-28 | BIVI | Biovie Inc. | Chappell Amy Suzon | Dir | P - Purchase | $2.16 | +727 | 727 | New | +$1,570 | ||||||
2026-08-28 | BIVI | Biovie Inc. | Kim Joanne Wendy | CFO | P - Purchase | $2.18 | +2,500 | 3,441 | +266% | +$5,450 | ||||||
2026-08-27 | BIVI | Biovie Inc. | Do Cuong V | Pres, CEO | P - Purchase | $2.08 | +15,210 | 16,117 | >999% | +$31,637 | ||||||
2026-08-26 | PGEN | Precigen, Inc. | Kindler Jeffrey B | Dir | S - Sale | $7.44 | -185,000 | 17,100 | -92% | -$1,376,400 | ||||||
| AD | 2026-08-26 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale+OE | $111.39 | -4,090 | 11,486 | -26% | -$455,567 | |||||
| AD | 2026-08-25 | MNPR | Monopar Therapeutics | Anderson Raymond | Dir | S - Sale+OE | $111.98 | -3,142 | 5,373 | -37% | -$351,835 | |||||
2026-08-26 | ADPT | Adaptive Biotechnologies Corp | Owen Katey Einterz | Dir | S - Sale | $26.00 | -9,615 | 78,639 | -11% | -$249,990 | ||||||
| D | 2026-08-27 | FENC | Fennec Pharmaceuticals Inc. | Andrade Robert | CFO | S - Sale+OE | $11.78 | -75,000 | 239,603 | -24% | -$883,500 | |||||
| D | 2026-08-27 | ARQT | Arcutis Biotherapeutics, Inc. | Curran Terrie | Dir | S - Sale+OE | $25.03 | -38,200 | 23,526 | -62% | -$956,123 | |||||
| ADM | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | Walsh Colin | Dir | P - Purchase | $17.58 | +585,000 | 3,020,632 | +24% | +$10,285,000 | |||||
| AD | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | Walsh Colin | Dir | S - Sale+OE | $21.28 | -105,807 | 3,020,632 | -3% | -$2,251,658 | |||||
| M | 2026-08-26 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $72.26 | -25,000 | 1,499,860 | -2% | -$1,806,509 | |||||
| D | 2026-08-28 | ETON | Eton Pharmaceuticals, Inc. | Maier Paul V | Dir | S - Sale+OE | $59.07 | -50,000 | 59,745 | -46% | -$2,953,572 | |||||
2026-08-26 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $20.03 | -4,508 | 223,657 | -2% | -$90,295 | ||||||
| DM | 2026-08-26 | OMER | Omeros Corp | Hanish Arnold C | Dir | S - Sale+OE | $18.81 | -15,000 | 12,400 | -55% | -$282,094 | |||||
| D | 2026-08-27 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $522.57 | -9,500 | 668,728 | -1% | -$4,964,376 | |||||
2026-08-26 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $13.96 | -300 | 141,002 | 0% | -$4,188 | ||||||
| D | 2026-08-26 | CORT | Corcept Therapeutics Inc | Park Kimberly | Dir | S - Sale+OE | $122.55 | -26,685 | 0 | -100% | -$3,270,169 | |||||
| D | 2026-08-28 | IMVT | Immunovant, Inc. | Pande Atul | Dir | S - Sale+OE | $43.27 | -1,500 | 136,731 | -1% | -$64,905 | |||||
2026-08-26 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | S - Sale | $2.97 | -18,300 | 2,840,635 | -1% | -$54,351 | ||||||
| D | 2026-08-26 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale+OE | $13.69 | -77,000 | 69,828 | -52% | -$1,053,814 | |||||
| M | 2026-08-26 | JUSH | Jushi Holdings Inc. | Cacioppo James | CEO, 10% | P - Purchase | $0.49 | +994,000 | 16,618,577 | +6% | +$492,000 | |||||
2026-08-27 | JUSH | Jushi Holdings Inc. | Barack Louis Jon | Pres | P - Purchase | $0.50 | +30,000 | 2,913,773 | +1% | +$15,000 | ||||||
| DM | 2026-08-26 | MDWD | Mediwound Ltd. | Hess Shmuel | COO, Chief Commercial Officer | S - Sale+OE | $12.95 | -5,823 | 10,085 | -37% | -$75,394 | |||||
2026-08-25 | RLAY | Relay Therapeutics, Inc. | Svf Pauling (Cayman) Ltd | 10% | S - Sale | $19.40 | -6,000,000 | 21,904,963 | -22% | -$116,400,000 | ||||||
| D | 2026-08-26 | MNPR | Monopar Therapeutics | Rioux Patrice | Acting Chief Medical Officer | S - Sale+OE | $111.26 | -1 | 5,065 | 0% | -$111 | |||||
| DM | 2026-08-26 | RGNX | Regenxbio Inc. | Ciongoli Gregory Austin | Dir | P - Purchase | $9.25 | +102,603 | 118,035 | +665% | +$949,381 | |||||
| D | 2026-08-26 | GILD | Gilead Sciences, Inc. | Welters Anthony | Dir | S - Sale+OE | $148.62 | -18,000 | 12,894 | -58% | -$2,675,220 | |||||
2026-08-26 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale | $111.39 | -4,090 | 7,396 | -36% | -$455,567 | ||||||
2026-08-25 | MNPR | Monopar Therapeutics | Anderson Raymond | Dir | S - Sale | $111.77 | -3,142 | 23,751 | -12% | -$351,189 | ||||||
2026-08-20 | BMRA | Biomerica Inc | Gary M. Huff | Dir | P - Purchase | $1.60 | +31,250 | 51,250 | +156% | +$50,000 | ||||||
2026-08-26 | BMRA | Biomerica Inc | Moatazedi David | Dir | P - Purchase | $1.60 | +10,000 | 40,625 | +33% | +$16,000 | ||||||
2026-08-26 | BMRA | Biomerica Inc | Chin Eric | Dir | P - Purchase | $1.60 | +6,250 | 38,750 | +19% | +$10,000 | ||||||
2026-08-26 | BMRA | Biomerica Inc | Barbieri Allen | Exec Vice COB | P - Purchase | $1.60 | +20,000 | 73,542 | +37% | +$32,000 | ||||||
2026-08-26 | BMRA | Biomerica Inc | Irani Zackary S. | CEO | P - Purchase | $1.60 | +31,250 | 242,570 | +15% | +$50,000 | ||||||
2026-08-25 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $380.00 | -280 | 1,286,449 | 0% | -$106,400 | ||||||
| D | 2026-08-25 | ABT | Abbott Laboratories | Ford Robert B | COB, CEO | S - Sale+OE | $115.85 | -398,832 | 522,664 | -43% | -$46,204,798 | |||||
| D | 2026-08-26 | ODD | Oddity Tech Ltd | Drucker Mann Lindsay | Global CFO | S - Sale+OE | $15.01 | -3,493 | 104,492 | -3% | -$52,430 | |||||
| D | 2026-08-27 | IPAR | Interparfums Inc | Gabai-Pinsky Veronique | Dir | S - Sale+OE | $116.86 | -900 | 0 | -100% | -$105,173 | |||||
| D | 2026-08-26 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $517.28 | -9,500 | 668,728 | -1% | -$4,914,190 | |||||
2026-08-26 | CYPH | Cypherpunk Technologies Inc. | Dietz Thomas John | Dir | S - Sale | $1.72 | -20,000 | 132,500 | -13% | -$34,400 | ||||||
| D | 2026-08-25 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $125.58 | -30,955 | 119,472 | -21% | -$3,887,320 | |||||
2026-08-25 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO | S - Sale | $2.21 | -14,036 | 2,615,911 | -1% | -$30,969 | ||||||
2026-08-25 | QTTB | Q32 Bio Inc. | Morrison Jodie Pope | CEO | S - Sale | $16.56 | -9,845 | 343,259 | -3% | -$163,033 | ||||||
2026-08-25 | QTTB | Q32 Bio Inc. | Kalowski Lee | CFO, Pres | S - Sale | $16.56 | -3,972 | 138,471 | -3% | -$65,776 | ||||||
2026-08-25 | QTTB | Q32 Bio Inc. | Violette Shelia M. | Chief Scientific Officer | S - Sale | $16.56 | -2,798 | 164,048 | -2% | -$46,335 | ||||||
| D | 2026-08-25 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $151.98 | -41,570 | 770,729 | -5% | -$6,317,760 | |||||
2026-08-27 | INDV | Indivior Pharmaceuticals, Inc. | Anderson Woodrow D | Chief Accounting Officer | P - Purchase | $35.69 | +1,500 | 27,638 | +6% | +$53,535 | ||||||
2026-08-26 | IMTX | Immatics N.V. | Perceptive Advisors LLC | Dir | P - Purchase | $8.69 | +863,060 | 11,246,516 | +8% | +$7,499,991 | ||||||
| A | 2026-08-20 | PG | Procter & Gamble Co | Aguilar Moses Victor Javier | Chf Rsch, Dev, Innov Officer | S - Sale | $143.79 | -3,053 | 57,416 | -5% | -$438,991 | |||||
| D | 2026-08-26 | CHD | Church & Dwight Co Inc /De/ | Linares Carlos G. | EVP Chief Tech, Global New Pro | S - Sale+OE | $103.00 | -15,375 | 6,426 | -71% | -$1,583,625 | |||||
| M | 2026-08-24 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $7.36 | -62,714 | 4,318,348 | -1% | -$461,546 | |||||
| M | 2026-08-24 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.P. | 10% | S - Sale | $7.36 | -62,714 | 4,318,348 | -1% | -$461,546 | |||||
| DM | 2026-08-24 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $83.10 | -9,096 | 54,324 | -14% | -$755,852 | |||||
2026-08-17 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $8.08 | -5,062 | 132,775 | -4% | -$40,883 | ||||||
2026-08-25 | ANIP | Ani Pharmaceuticals Inc | Lalwani Nikhil | Pres, CEO | S - Sale | $74.30 | -5,400 | 344,489 | -2% | -$401,220 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Kaiser Peter | Chief Development Officer | S - Sale | $10.77 | -3,035 | 264,378 | -1% | -$32,687 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Nayak Sanjay | Chief Strategy Officer | S - Sale | $10.78 | -1,897 | 326,898 | -1% | -$20,450 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Heier Jeffrey S. | Chief Scientific Officer | S - Sale | $10.78 | -3,296 | 318,326 | -1% | -$35,531 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Dugel Pravin | See Remarks | S - Sale | $10.77 | -21,649 | 3,270,332 | -1% | -$233,160 | ||||||
2026-08-24 | CAMP | Camp4 Therapeutics Corp | Schwab Andrew J. | Dir | S - Sale | $4.50 | -10 | 5,677,216 | 0% | -$45 | ||||||
2026-08-24 | CL | Colgate Palmolive Co | Tsourapas Panagiotis | COO, CD, EMEA, APac, Skin | S - Sale | $92.05 | -10,000 | 78,594 | -11% | -$920,477 | ||||||
| D | 2026-08-25 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $517.71 | -9,500 | 668,728 | -1% | -$4,918,273 | |||||
| D | 2026-08-25 | TECX | Tectonic Therapeutic, Inc. | McNamara Peter | Chief Scientific Officer | S - Sale+OE | $36.52 | -43 | 55,285 | 0% | -$1,570 | |||||
| M | 2026-08-24 | ANL | Adlai Nortye Group Ltd. | Ye Xiaofeng | CFO | S - Sale | $14.11 | -11,667 | 147,757 | -7% | -$164,635 | |||||
2026-08-25 | BMY | Bristol Myers Squibb Co | Holzer Phil M | SVP, Controller | S - Sale | $67.50 | -500 | 16,862 | -3% | -$33,750 | ||||||
| M | 2026-08-24 | JUSH | Jushi Holdings Inc. | Cacioppo James | CEO, 10% | P - Purchase | $0.48 | +706,112 | 15,624,577 | +5% | +$342,154 | |||||
2026-08-25 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $49.57 | -18,921 | 569,645 | -3% | -$937,957 | ||||||
| D | 2026-06-04 | EVGN | Evogene Ltd. | Tarcic Gabi | Chief Development Officer | P - Purchase | $0.60 | +1,129 | 1,129 | New | +$677 | |||||
| M | 2026-08-24 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Chief Development Officer | S - Sale | $50.47 | -50,160 | 195,862 | -20% | -$2,531,582 | |||||
| D | 2026-08-24 | CBT | Cabot Corp | Keohane Sean D | Pres, CEO | S - Sale+OE | $85.50 | -2,779 | 303,137 | -1% | -$237,605 | |||||
| D | 2026-08-25 | CHD | Church & Dwight Co Inc /De/ | Hemsey Rene | EVP, CHRO | S - Sale+OE | $102.26 | -5,000 | 14,429 | -26% | -$511,275 | |||||
2026-08-25 | CVM | Cel Sci Corp | Kersten Geert R | CEO | P - Purchase | $1.38 | +100,000 | 627,689 | +19% | +$138,000 | ||||||
| M | 2026-08-24 | PRE | Prenetics Global Ltd | Rosin Brian J | CFO of IM8 (US) LLC | P - Purchase | $21.55 | +23,100 | 23,100 | New | +$497,700 | |||||
2026-08-24 | MAIA | Maia Biotechnology, Inc. | Guerrero Ramiro | Dir | P - Purchase | $1.33 | +1,794 | 601,911 | 0% | +$2,386 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |